GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » Issuance of Stock

Ascletis Pharma (HKSE:01672) Issuance of Stock : HK$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma Issuance of Stock?

Ascletis Pharma's Issuance of Stock for the six months ended in Dec. 2023 was HK$0.00 Mil.

Ascletis Pharma's Issuance of Stock for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00 Mil.


Ascletis Pharma Issuance of Stock Historical Data

The historical data trend for Ascletis Pharma's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma Issuance of Stock Chart

Ascletis Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Issuance of Stock
Get a 7-Day Free Trial - - - 1.07 -

Ascletis Pharma Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Issuance of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.13 - - - -

Ascletis Pharma Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascletis Pharma Issuance of Stock Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascletis Pharma Business Description

Traded in Other Exchanges
Address
198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other countries.
Executives
Wu Jinzi Jason 2101 Beneficial owner
Wu Judy Hejingdao 2101 Beneficial owner
Jjw12 Limited
Lakemont Holding Llc
Jjw11 Limited
C-bridge Capital Gp, Ltd. 2201 Interest of corporation controlled by you
Fu Wei 2201 Interest of corporation controlled by you
Tf Capital Ii Ltd. 2201 Interest of corporation controlled by you
Tf Capital, Ltd. 2201 Interest of corporation controlled by you
Kang Hua Investment Company Limited 2201 Interest of corporation controlled by you
Yang Dan 2201 Interest of corporation controlled by you

Ascletis Pharma Headlines

No Headlines